Calypte an der OTC - 500 Beiträge pro Seite

[tst89]

Hallo allerseits!

Irgendwie macht mir die Entwicklung von Calypte zunehmend Sorgen. Nach Präsentation der letzten Quartalszsahlen (die ja leicht besser als erwartet waren) und der Pressekonferenz (die ein bisserl ermutigend bezüglich Finanzpartnern war) geht der Kurs an der OTC nur noch stetig nach unten.

Hat jemand eine Ahnung woran das liegt
und
wie es weitergehen wird???

Gruß
tst

[Die Stimme]

noch nicht

[ab@h]

@all

Bei Recherchen im RB-Board bin ich auf eine neue Calypte-Community bei MSN gestoßen: http://communities.msn.com/Calypte/_whatsnew.msnw

Neben einem Message-Board gibt`s auch ein paar Fotos von einer Besichtigungstour bei CALY (incl. Guppenfoto der Mitarbeiter). Sehr interessant...

ciao

ab

[Lima2000]

Schlusskurs an der OTC 0,31$
Hoffentlich nur die Ruhe vor dem Sturm!

[lister]

@all
Leute wir sind hier an der OTC und Caly hat
seit dem sie dort ansässig sind erstaunlich
gute Tagesvolumen. Das heißt der Wert ist nicht
uninteressant. Instis haben heute gerade mal
9% der Umsatzes ausgemacht und das nach 2:00pm.
Es wurden auch rel. viele Stücke >10000 verschoben
allerdings mit trades zum ask und zum bid.
Beim letzten Delisting-Ausverkauf waren 80% der
trades zum bid.

Es ist durchaus möglich das jetzt die große Zeit
der Pump and Dump Fraktion kommt und wir sogar noch
wesentlich tiefere Kurse sehen werden.
Für die wäre es natürich ein Leckerbissen Caly
auf ,15$ zu drücken und sollte es dann zu einem
Deal kommen....

Wer an der OTC solche Schwankungen nicht verkraftet
sollte sich das nicht antun.

Grüße lister

[sunny66]

servus @all
bin neu hier im board.
habe mir die letzten wochen viele postings von euch durchgelesen. bin auch sehr von caly überzeugt und natürlich investiert. wünsche allen toi toi toi.
gruß sunny

[tst89]

Hat jemand eine Ahnung wann es mit Calypte wieder entweder aufwärts oder abwärts gehen wird?? Hat da jemand Infos??

Momentan kann man dies doch nur als Ruhe vor dem Sturm betrachten. Doch wie lange dauert diese Ruhe noch???

Hoffentlich nicht bis Caly pleite ist.....

Besorgte Grüße
tst

[ab@h]

@tst89

Wie es weitergehen wird weiß z.Zt. niemand so recht. Wenn Du aber wissen willst, wie die Amis über CALY denken, kann ich Dir ein interessantes Board empfehlen:

http://communities.msn.com/Calypte/_whatsnew.msnw.

Da ist mehr los als bei RB und Du kannst Dir in der Fotogalerie auch mal die Verantwortlichen direkt anschauen.

ciao

ab

[ab@h]

@tst89

Sorry, aber ich hab übersehen, daß ich Dir den Link schon letzte Woche reingestellt habe.

Das kann nur an der Hitze liegen....



ab

[tst89]

@abah

trotzdem vielen Dank!!!

Gruß
tst

[tst89]

0,22$????

Das ist aber die falsche Richtung.....

[tst89]

Updated 03:12 PM EDT, Oct-5-2001

PIPEs financings draw critical eye on Batliner

by Stacy Mosher
Posted 05:45 PM EDT, Oct-4-2001



See the companies listed in the report with PIPE financing.


A report calling for an investigation into private investments in public entities, or so-called PIPEs financing, involving an offshore law firm suspected of money laundering has been submitted to the U.S. Senate`s permanent subcommittee on investigations on Capitol Hill.

The equity-line financings examined in the report — compiled by an anonymous market professional and based in part on investigative reporting by The Daily Deal — were all provided by trustee companies of a Liechtenstein law firm, Dr. Dr. Batliner & Partner.

Herbert Batliner, head of the Batliner law firm, is the subject of money laundering and tax evasion investigations in Germany and in his native Liechtenstein, which has recently taken measures to clean up its reputation as a money laundering center in Europe.

The ultimate ownership of the Batliner companies investing in PIPEs with U.S. companies is unknown. But Batliner is known to have handled funds for a number of questionable individuals.

Most recently, a federal court in Florida in June granted a request for judicial assistance from authorities in Liechtenstein in relation to an investigation into trust companies the Batliner firm handled for an alleged Ecuadorian drug trafficker, Jorge Hugo Reyes Torres.

The 300-page report was sent to Sen. Carl Levin, D-Mich., chairman of the subcommittee, which has been investigating money laundering in the U.S. financial industry. Copies of the report have also been sent to the U.S. Securities and Exchange Commission, the U.S. attorney general and a variety of other government agencies, including the Federal Bureau of Investigation, the Drug Enforcement Administration and U.S. attorneys in New York and Florida.

The analysis, focusing on equity-line financings and convertible debentures, raises questions about whether private placement financings for small U.S. public companies may have been used for money laundering, tax evasion and stock manipulation to the detriment of the companies involved.

Equity-line financing and certain types of convertible debentures have been tagged "toxic financing" because they offer the potential for stock manipulation to the alleged benefit of the lender. Proponents of equity lines and convertibles, however, maintain that a well-formulated agreement will protect companies from shorting and other manipulation. Properly constructed PIPEs instead allow investing companies to hedge their risk in financially vulnerable companies.

The report identified PIPE financings provided by Batliner-linked companies between 1997 and the beginning of 2001 through SEC filings. The 60 companies identified included 18 receiving convertible debentures and 42 receiving equity lines, sometimes coupled with convertibles.

Calls to the Batliner law firm were not returned by press time.

Companies listed in the report with PIPE financing
Advanced Communications Technologies Inc. (ADVC)
Alpnet Inc. (AILP)
Cellpoint Inc. (CLPT)
General Magic Inc. (GMGC)
Imaginon Inc. (IMON)
A.B. Watley Group Inc. (ABWG)
Ameriquest Tech (AMQT)
Beyond.com Corp. (BYND)
Cambex Corp. (CBEX)
Cavion Tech (CAVNQ)
Dauphin Technology Inc. (DNTK)
Driversshield.com Corp. (DRVR)
Generex Biotech (GNBT)
Innovacom Inc. (MPEG)
Metalclad Corp. (MTLC)
Mortgage.com Inc. (MDCM)
MW Medical Inc. (MWMD)
Nastech Pharmaceutical Co. (NSTK)
Nstor Technologies Inc. (NSO)
Pawnbroker.com (PBRRE)
Talk Visual CP (TVCP)
Affinity Technology Group Inc. (AFFI)
Dental/Medical Diagnostic Systems Inc. (DMDS)
Diversified Senior Services (DISS)
Ecogen Inc. (EECN)
Hawaiian Natural Water Co. (HNWC)
Hollywood Media Corp. (HOLL)
Imsco Technologies Inc. (IMSO)
Milestone Scientific Inc. (MS)
Pen Interconnect Inc. (PENC)
Professional Transportation Group (TRUC)
Sedona Corp. (SDNA)
Surgilight Inc. (SRGL)
SVI Solutions (SVI)
Webcatalyst (WBCL)
APA Optics Inc. (APAT)
Appiant Technologies Inc. (APPS)
Aquis Communications Group Inc. (AQIS)
Brilliant Digital Entertainment (BDE)
Calypte Biomedical Corp. (CALY)
Clicknsettle (CLIK)
Cytrx Corp. (CYTR)
Esynch Corp. (ESYN)
Famous Fixins Inc. (FIXN)
Focus Enhancements Inc. (FCSE)
Imaging Technologies Corp. (ITEC)
Inchorus.com (ICHC)
McGlen Internet Group Inc. (MIGS)
Media X Corp. (MXMX)
Medisys Technologies Inc. (SCEP)
Netlojix Communications Inc. (NETX)
Nymox Pharmaceutical Corp. (NYMX)
Objectsoft Corp. (OSFT)
Pet Quarters Inc. (PDEN)
Pharmos Corp. (PARS)
Sand Technology Inc. (SNDT)
Viragen Inc. (VRA)
Waverider Communications Inc. (WAVC)
Wealthhound.com Inc. (WLTH)
Worldwide Wireless Networks (WWWN)

[tst89]

Hier nocheinmal der Pressetext, diesmal jedoch MIT Zahlen:


Press Release
SOURCE: Calypte Biomedical

Calypte Reports Third Quarter 2001 Financial Results

Revenues Increase 75% Compared With Third Quarter 2000

ALAMEDA, Calif.--(BW HealthWire)--Oct. 18, 2001--Calypte Biomedical Corporation (OTCBB:CALY - news) announced today that its revenues for the third quarter ended September 30, 2001 increased 75% to $1,465,000 compared to $835,000 for the same period last year. Revenues for the nine months ended September 30, 2001 were $4,478,000, compared with $2,720,000 for the first nine months of last year, an increase of 65%.

``While revenues from all products increased compared to third quarter 2000 levels, third quarter 2001 revenues from the sale of the company`s HIV-1 Western Blot serum assay more than doubled``, said Nancy Katz, President, Chief Executive Officer, and Chief Financial Officer of Calypte. ``We are very pleased with our 2001 operating results to date.``

``Revenues for the first nine months of 2001 already exceed those of full-year 2000 by 36%. The temporary product supply interruptions we experienced during the third quarter have been resolved and, looking forward, we expect strong performance during the fourth quarter. As blood donations across the nation have reached unparalleled levels, we are experiencing a significant increase in demand for our serum Western Blot test. Our employees are working seven days a week to meet the demands of blood banks, the military and other organizations monitoring the safety of the nation`s blood supply and these organizations have our highest priority in product availability. We expect to exceed $7 million in revenues for the full year 2001,`` Katz said.

Calypte`s domestic urine HIV testing business also continues to grow. Sales to the reference labs supporting the domestic life insurance business increased by more than 40% for the first nine months of 2001 compared to the same period in 2000. The major life insurance companies continue to expand their acceptance of urine testing as a part of their underwriting standards and Calypte now counts nine of the ten ``most admired`` life insurance companies, as identified by Fortune magazine, as among those companies using its urine test to screen policy applicants. The company`s sales force closed a number of new Sentinel Testing Service accounts during the third quarter and has a number of product evaluations in process across the country.

Katz continued, ``With this demonstrated base of support for urine-based testing, Calypte is developing a urine based rapid test for the detection of HIV-1 as its highest new product priority. Results of laboratory testing to this point have encouraged us to continue the development of this new product.``

Calypte completed its first urine HIV-1 antibody test shipment of significant size to its distributor in the People`s Republic of China earlier this week and expects another order and shipment later this quarter. These tests are destined for epidemiological uses in at least 20 of the country`s 28 provinces. China has recently announced the creation of a Five Year Plan against HIV/AIDS and HIV epidemiological baseline screening combined with ongoing surveillance will be key elements of the plan. The company expects its products to play a key role in this effort as the Plan is implemented.

During the third quarter, Calypte completed its first shipment of urine HIV-1 EIA tests to its distributor in Malaysia. That distributor is optimistic that additional regulatory reviews currently in process will expand the market for the company`s tests to additional public and private sector entities in Malaysia. The regulatory approval process is moving forward in both the Philippines and South Korea, where, in both cases, the company expects to receive a formal request for a small clinical evaluation in the near future. Calypte is also working with its distributor in Brazil to formulate the protocol for a local clinical trial that has been requested by regulatory authorities. In cooperation with its new distributors in Thailand and Taiwan, the company plans to make regulatory submissions to the appropriate authorities shortly. Although Calypte already has regulatory approval in the Republic of South Africa, its distributor for that territory and other countries in sub-Saharan Africa has undergone a corporate restructuring that has disrupted sales efforts for the company`s tests. The company is actively looking to expand its distribution channels in those territories. The company continues to actively seek product evaluations and regulatory approval in a number of other international venues, including Mexico and France.

The company has reduced its burn rate significantly compared to the prior year. The net loss for the third quarter improved by $1.4 million from a year ago. The net loss attributable to common stockholders for the third quarter of 2001 was $1.7 million, or $0.05 per share, compared with a net loss attributable to common stockholders of $3.1 million, or $0.13 per share, for the same quarter of 2000. The net loss attributable to common stockholders for the first nine months of 2001 was $8.1 million, or $0.27 per share, compared with a net loss attributable to common stockholders of $8.6 million, or $0.37 per share, for the first nine months of last year.

During the third quarter, Calypte continued the aggressive cost control measures implemented earlier in the year. Coupled with its increased revenues, those measures continue to generate improved margins at the company`s Alameda, Calif. and Rockville, Md. manufacturing facilities. As a further cost reduction step, the company plans to reduce the size of its Rockville, Md. manufacturing facility. This change will not impact workforce size, product supply or quality from that plant, but by reducing space needs by approximately 50%, the company expects to reduce operating costs by approximately $400,000 annually.

``Based on the growth that we project both domestically and internationally, we remain on track to double revenues in 2002 compared to calendar year 2001 and to achieve profitability in the fourth quarter of 2002,`` Katz continued. ``But, as the company`s cash on-hand as of September 30, 2001 was $48,000 and with negative working capital of $4.9 million, we will require additional external financing to continue our current level of operations through the fourth quarter of 2001. The company expects to register the equity line of financing announced in September in the near future and plans to begin drawing on the line once the SEC declares the registration statement effective. At this time, however, we are unable to predict how longthe SEC review process might take. Beyond the equity line, although we do not have any financing agreements in place, we are continuing to investigate funding sources that can enable the company to achieve its milestones. There can, however, be no assurance that additional capital will be available to the Company on acceptable terms, or at all,`` Katz concluded.

Calypte Biomedical Corporation (OTC Bulletin Board: CALY - news) headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte`s tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company also markets one of only two FDA-approved HIV-1 supplemental Western Blot tests available for testing serum samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in over 40 countries worldwide through international distributors and strategic partners.

Statements in this press release that are not historical facts are forward-looking statements, including statements regarding future revenues and sales projections, plans for future financing, the ability to meet operational milestones, and shipments to andregulatory approvals in international markets. Such statements reflect management`s current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our product in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company`s expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company`s success are more fully disclosed in the Company`s most recent public filings with the U.S. Securities and Exchange Commission (``SEC``), including its annual report on Form 10-K for the year ended December 31, 2000 and its subsequent filings with the SEC.

Calypte Biomedical has scheduled a conference call to discuss financial results for the third quarter at 11:00 a.m. (EDT) on Friday, October 19, 2001. All interested parties are invited to listen to this call. To listen to the call from the US, please dial 1-888-997-8642 and ask to be connected to the Calypte conference call. International callers please dial 973-694-6836. This conference call will also be webcast on the Internet. A link to a live broadcast of the call on the Internet can be found at ``Investor`` at www.calypte.com or at www.companyboardroom.com.

If you are unable to participate, a rebroadcast of the call will be available beginning 2:00 p.m. (EDT) on Friday, October 19, 2001 until Friday, October 26, 2001 at 2:00 p.m. (EDT). To access the rebroadcast domestically, please dial: 1-800-428-6051, conference no.: 213772. International callers please dial: 973-709-2089. To access a rebroadcast of the webcast, please visit ``Investor`` at www.calypte.com or visit www.companyboardroom.com.

-0-

CALYPTE BIOMEDICAL CORPORATION AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
Unaudited

Three Months Ended Nine Months Ended
Sept. 30, June 30, Sept. 30, September 30,
2001 2001 2000 2001 2000
-------- -------- -------- -------- --------

Revenues:
Product sales $ 1,465 $ 1,612 $ 835 $ 4,478 $ 2,720
-------- -------- -------- -------- --------
Cost of product
sales 1,486 1,743 1,588 5,218 4,312
-------- -------- -------- -------- --------
Loss on product
sales (21) (131) (753) (740) (1,592)

Other operating
expenses:
Research and
development
costs 351 354 496 1,201 1,612
Selling, general and
administrative
costs 1,249 2,138 1,915 5,343 5,437
-------- -------- -------- -------- --------
Total other
operating expenses 1,600 2,492 2,411 6,544 7,049
-------- -------- -------- -------- --------
Loss from
operations (1,621) (2,623) (3,164) (7,284) (8,641)

Interest income 1 1 85 8 247
Interest expense
(non-cash expense
of $830 for the
three months ended
June 30, 2001 and
$1,318 for nine
months of 2001) (6) (838) (29) (1,357) (93)
Other income
(expense) -- 501 5 524 4
-------- -------- -------- -------- --------
Loss before
income taxes (1,626) (2,959) (3,103) (8,109) (8,483)

Income taxes -- -- -- (2) (2)
-------- -------- -------- -------- --------
Loss before
extraordinary
item (1,626) (2,959) (3,103) (8,111) (8,485)
Extraordinary gain
on repurchase of
beneficial conversion
feature, net of
tax expense -- 145 -- 145 --
-------- -------- -------- -------- --------
Net loss (1,626) (2,814) (3,103) (7,966) (8,485)

Less dividends on
mandatorily redeemable
Series A preferred
stock (30) (30) (30) (90) (90)
-------- -------- -------- -------- --------
Net loss
attributable
to common
stockholders $ (1,656) $ (2,844) $ (3,133) $ (8,056) $ (8,575)
======== ======== ======== ======== ========
Net loss per share
attributable to
common stockholders
(basic and diluted) $ (0.05) $ (0.10) $ (0.13) $ (0.27) $ (0.37)
======== ======== ======== ======== ========
Weighted average
shares used to
compute net loss
per share
attributable
to common
stockholders
(basic and diluted) 33,153 29,070 24,969 29,373 23,362
======== ======== ======== ======== ========


CALYPTE BIOMEDICAL CORPORATION AND SUBSIDIARY
CONSOLIDATED BALANCE SHEET DATA
(in thousands)
Unaudited

Sept. 30, Dec. 31,
2001 2000
-------- --------
Cash, cash equivalents, and restricted cash $ 48 $ 1,203
Working capital (4,867) (875)
Total Assets 3,524 5,006
Current portion of notes payable 400 471
Long-term portion of capital lease obligations 56 78
Mandatorily redeemable
Series A preferred stock 2,426 2,336
Total stockholders` equity (5,943) (1,531)

------------------------------------------------------------------------
Contact:

Calypte Biomedical
Nancy Katz, 510/749-5100
www.calypte.com

[tst89]

Hier ein interessanter Bericht (Caly wird ungefähr in der Mitte
erwähnt - durchaus positiv! )



Thursday November 1, 7:04 am Eastern Time

Press Release

SOURCE: Burill & Company

Biotech Stocks Rebound in October

Bioterrorism Keeps the Industry in the Limelight

SAN FRANCISCO, Nov. 1 /PRNewswire/ -- Fears about bioterrorism rose dramatically during October as sophisticated forms
of anthrax were discovered in letters sent to several members of the media and individuals within branches of the U.S. government.
The incidents have sparked tremendous concern, not only regarding anthrax, but also the threat of other bioweapons being
released onto the public. The current emphasis on prevention, detection, and potential treatment of illnesses caused by bioterrorist
activities has kept the focus on the biotech sector steadily during the month and the overall effect on stocks has been positive.

``Biotech has more than held its own during a `recovering` month for most of the market,`` noted G. Steven Burrill, CEO of Burrill
& Company, a San Francisco-based life sciences merchant bank. ``With consumer confidence worse than it has been in seven
years and the economy receding at 1% annual rate, many segments of the market took a beating, but biotech took center stage as
part of the nation`s hope against biowarfare.``

The Burrill Biotech Select Index gained 17% for the month (down 28% YTD) while the NASDAQ was up nearly 13% for the
month (down 31% YTD) and the DOW gained just under 3% in October (off nearly 16% YTD).

``The slight rally we saw early in the month was undermined by a growing sense of insecurity, both global and domestic,`` said
Burrill. ``Clearly, though, investors realize that biotech has an increasingly important role to play in today`s unsettled world.``
Indeed, Cepheid, which makes portable detectors of food and water contaminants, including anthrax and smallpox, has attracted a
great deal of interest with stocks soaring nearly 300% since the September 11 terrorist attacks and up 178% for the month. Other
firms have seen major gains as well. BioReliance, a company that makes a smallpox vaccine, has experienced 117% increase in
share prices since September 10, 2001. Nanogen`s shares rose 86% during October. The company, which has received over
$14.5 million in government funding and commitments to support its biowarfare and human identification efforts, has created and
delivered to the U.S. government a prototype portable field-based detection device and is currently developing additional
products, including assays, for detecting biowarfare agents and infectious diseases.

``... But, there`s more to the rebound than bioterrorism,`` Burrill commented. ``Many biotech stocks were trading at or near cash
value at the start of the month, offering investors low cost of entry with a large potential upside since the industry`s fundamentals
remain strong,`` he explained. ``Then, too, a number of companies including Affymetrix (up 87%), Calypte Biomedical Corporation
(up 60%), Orchid Biosciences (up 83%), Matritech (up 91%), and Ariad Pharmaceuticals (up 60%), had news worthy of
sparking major investor interest.

Affymetrix, with its stock up 87% for the month, announced a narrower third-quarter loss ($1.8 million, excluding special charges)
than analysts expected and projected 2002 revenue growth of 25% over an expected total of $190 million this year. In addition,
Affymetrix is extending its genetic technology beyond health care into the area of nutraceuticals. Nestle S.A. is using Affymetrix` gene chips to explore nutrition on a
molecular level to develop healthier products.

Affymetrix also announced a co-development agreement with Millennium, whereby the two companies would create a new generation of GeneChip® technology
designed to speed the drug development process. Millennium`s shares gained 43% during the month.

Another huge gainer during October was Odwalla, the maker of Fresh Samantha juices. The world`s number one soft drink company, Coca-Cola, agreed to pay
about $181 million-a premium of $50 million over its market cap of $131 million. Odwalla`s stock increased by 143% during the month. ``This deal addresses the
consumer`s desire for juice and soy-based beverages as an alternative to soft drinks,`` said Burrill. ``The move enables Coca-Cola to migrate further into the health
foods arena-a segment that is expected to prosper in our wellness-oriented future,`` he commented. ``Nutraceuticals is once again an attractive place to invest.``

Another area that experienced growth was diagnostics. The Burrill Diagnostic Fund was up nearly 13% for the month (down 19% YTD), with some players doing
exceptionally well. Cepheid, Orchid BioSciences, Inc., Myriad, Third Wave Technologies, Inc., Digene Corporation, Quidel Corporation, and Bio-Rad Labs all
posted significant double-digit gains. ``Calypte has posted third quarter revenues that are 75% higher than the same period last year,`` explained Burrill. ``The sale of
the company`s HIV-1 Western Blot serum assay more than doubled and with blood donations across the country reaching record levels, that demand can only
increase.``

The Burrill Genomics Index grew by almost 30% during the month (down 43% YTD). In addition to stellar performances by Affymetrix, Nanogen, and Millennium,
Human Genome Sciences` stock gained 38% despite a widening third- quarter loss and Caliper Technologies` stock climbed 27%, after the company posted
third-quarter revenues of $6.6 million, compared to $5.5 million a year ago.

The Burrill Large-Cap Index gained 14% (down 18% YTD). Genentech, beating Wall Street`s earning estimates by a penny, saw a 19% increase during the month.
Sales of the company`s anti-cancer drug, Rituxan®, which Genentech developed with IDEC Pharmaceuticals, were $212.8 million-a 13% increase over second
quarter sales. Genentech also announced increased sales of Herceptin® and Pulmozyme®.

The Burrill Mid-Cap Index was up 19% for the month (down 26% YTD). The majority of the companies posted healthy double-digit growth. In addition to Orchid,
EntreMed (up 35%), Ligand Pharmaceuticals (up 47%) and Transkaryotic Therapies (up 40%) all turned in strong performances.

The Burrill Small-Cap Index gained nearly 15% during October (down 14% YTD). Matritech, Inc. experienced a 90% gain on news that a prostate cancer market
identified by the company`s scientists detected prostate cancer with greater sensitivity than the prostate specific antigen (PSA) test. Shares of Ariad Pharmaceuticals
gained 60% during the month, based largely on the company`s announcement of the discovery of experimental compounds that could potentially be used to fight
cancer. Boston Life Sciences also posted gains of 67%.

The Burrill Nutraceuticals Index, bolstered in large measure by the Coca- Cola/Odwalla deal, gained 8%. Cyanotech, the world leader in producing microalgae
products posted a 54% increase for the month. While sales were lower, during the first six months of the fiscal year, the company saw sales of its packaged
consumer products increase by more than 60%. Integrated Health Technologies (up 21% for the month) has had a healthy upswing in sales. During the fourth
quarter, sales increased by 90% for the same period a year ago, signaling what the company believes is the trend for the future.

The Burrill Agbio Index gained only 3% (down 20% year to date). Bionova Holding Corporation (down 56%) and EDEN Bioscience Corporation (down 38%)
were the biggest losers.

A review of the Burrill Life Sciences Indices for August 2001 is as follows:

Index 12/31/00 9/30/01 10/31/01 Percent Percent
Value Value Value Change Change
for YTD
Month
Burrill Life
Science Composite
Index 183.2 139.63 155.47 11.34% -15.14%
Burrill Biotech
Select Index 412.97 253.31 296.85 17.19% -28.12%
Burrill LARGE-CAP
Biotech Index 387.93 275.24 315.31 14.56% -18.72%
Burrill MID-CAP
Biotech Index 284.78 176.06 209.62 19.07% -26.39%
Burrill SMALL-CAP
Biotech Index 187.79 140.04 161.25 15.14% -14.13%
Burrill Agbio
Index 87.64 67.55 69.64 3.10% -20.54%
Burrill Animal
Health Index 96.87 114.25 120.75 5.69% 24.66%
Burrill Genomics
Index 421.53 183.93 238.80 29.83% -43.35%
Burrill Bioma-
terials/
Bioprocess
Index 132.04 101.73 100.62 -1.10% -23.80%
Burrill Diagnostic
Fund 100 71.52 80.69 12.82% -19.31%
Burrill
Nutraceuticals
Index 105.36 102.55 111.07 8.31% 5.42%


Index 12/31/00 9/30/01 10/31/01 Percent Percent
Value Value Value Change Change
for YTD
Month
Burrill Biotech
Select Index 412.97 253.31 296.85 17.19% -28.12%
NASDAQ 2471.43 1498.80 1690.20 12.77% -31.61%
DJIA 10787.99 8847.56 9075.14 2.57% -15.88%
Russell 2000 483.53 404.87 428.17 5.75% -11.45%




Burrill & Company

Burrill & Company is a life sciences merchant bank, focused exclusively on companies involved in biotechnology, pharmaceuticals, diagnostics, human healthcare,
related medical technologies, agricultural technologies, animal health, nutraceuticals, and biomaterials/bioprocesses.

Venture Capital

The Burrill family of venture capital funds, with over $325 million under management, includes the Burrill Biotechnology Capital Fund, the Burrill Diagnostics Fund,
the Burrill Agbio Capital Fund, the Burrill Nutraceuticals Capital Fund, the Burrill Biomaterials/Bioprocess Capital Fund and the Burrill Life Science Capital Fund,
currently under development.

Strategic Partnering

Burrill & Company assists life science companies identify, negotiate and close strategic partnerships providing access to resources, technologies or collaborations
essential for executing their business plans. We have completed more than 20 strategic partnerships with a value in excess of $1 billion.

Spin-outs/Spin-ins

Burrill & Company works with major life science companies to spin-out internal assets and capitalize on their value, ranging from the outright sale of products or
businesses to creation of new companies to exploit these assets. We also use our extensive network to help companies identify, assess and capture (``spin-in``)
products and companies strategic to building their businesses.

For more information, please visit Burrill & Company`s website at www.burrillandco.com.

SOURCE: Burill & Company

[tst89]

Was ist los mit Calypte?? Hat jemand eine Ahnung ob irgendwelche News anstehen. Es müsste sich doch langsam mal in irgendeine Richtung (nach immer nur positiven News steht der Kurs mehr oder minder fest - pendelt nur minimal).

Gruß
tst

[tst89]

China AIDS protest

Chinese Aids sufferers stage mass protest
By James Kynge in Beijing
Published: November 22 2001 20:40
Last Updated: November 22 2001 21:47

Several hundred Chinese villagers protested this week outside a local government office demanding free medicine after claiming that botched collections of blood left them infected with HIV.
Witnesses told the Financial Times that Aids sufferers and HIV carriers, mainly from the central province of Henan, began demonstrating at a government office in Chengguan town on Monday.
Their demands had not been met by Thursday in spite of talks between local authorities and protesters, witnesses said.
The Aids issue is potentially explosive for the Chinese government because there are numerous villages in Henan - more than 50 according to one local expert - in which a high proportion of the population has contracted HIV after the sale of blood in the 1990s to negligent companies often run by local officials.
Dirty needles were regularly reused, spreading the virus. The blood collected was then often pooled, contaminating blood banks kept for transfusions.
An almost complete ignorance of HIV and Aids in the region until recently contributed to transmission through sexual contact.
The local population is poor and it was not uncommon for people to sell their blood 20 times a month, receiving about Rmb40 (£3.40) for 500ml, said Zhao Yong, an HIV carrier in Henan whose wife has died of Aids.
In some Henan villages, more than 60 per cent of the population is infected, experts say.
China has kept its Aids problem virtually taboo until last week, when it held its first international conference on Aids and acknowledged about 600,000 cases nationwide.
Some health experts and one official newspaper said the government grossly underestimated the number of sufferers.
The demonstration in Chengguan appears to have been prompted in part by the detention of a camera crew from CCTV, the official Chinese TV broadcaster, and a Beijing doctor, who were making a report on the plight of those infected.
Residents welcomed the doctor and the journalists, believing they might help their quest for compensation and free medicine. But local officials, who stood to lose prestige and possibly their jobs, detained the visitors and expelled them from the area.
The appetite for compensation has been sharpened by the publicised case last week of a court award of $43,770 (£31,011) compensation for a four-year-old girl in the northern province of Hebei whose mother died of Aids in 1999 after receiving contaminated blood following the girl`s birth.

[biologist]

@tst89

Den Artikel habe ich auch gelesen (im Yahoo Message Board)! Um Unruhen im eigenen Land vorzubeugen, wäre es für die chinesische Regierung ratsam etwas gegen die Ausweitung von Aids zu unternehmen.
Eine Möglichkeit: Testen von Blutkonserven - und das möglichst billig und schnell. Nur hierfür wäre ein Markt für Caly`s Produkte vorhanden.
Der Rest fällt den Equipment-Zulieferern zu, die für steriles Zubehör zu sorgen haben.

cu biologist

[rjenzi]

Habe mir mal kurz die Zahlen von CALY angeschaut. Etwas passt mir da gar nicht in den Kram:

Product Sales: $ 1`465`000
Cost of Product Sales: $ 1`486`000

Warum ist das so (hohe Fixkosten)? Wie und wann wird sich das aendern? Danke schon im Voraus fuer Antworten...

[biologist]

@rjenzi

Kann ich Dir erklären. Caly`s HIV-Urin-Test gibt es ja noch nicht all zu lange auf dem MArkt. Hier müssen zunächst Grundlagen geschaffen werden, um das Produkt bekannt zu machen, Absatzmärkte müssen erschlossen werden. Hiermit ist eine nicht ganz unerhebliche finanzielle Belastung verbunden, die sich in den Cost of Product Sales ausdrückt. Man schaue sich in Deutschland an, welche Werbegeschenke Pharmakonzerne durch ihre Pharmareferenten bei Tagungen oder Besuch von Laboren und Arztpraxen machen, auf denen natürlich der Name des neuen Produktes eingeprägt/aufgebracht ist. Das läuft in den US nicht anders.
Wenn eine Firma also ihre FDA-Zulassung bekommen hat, verdient sie trotzdem nicht sofort an ihrem neuen Produkt.
Außerdem hat Caly ja nun auch einen erfahrenen Distributor ins Boot geholt, der auch ganz gerne seine Auslagen beglichen haben möchte, der aber dafür bereits über genügend Connections verfügt. Schätze mal ganz grob, das dieses Zahlenverhältnis Ende Q4 besser aussehen wird.

cu biologist

[Marco111]

Wieder unter hohen Umsätzen über 8 % verloren.
Ich habe wenig Hoffnung das wir noch ne Wende bekommen,
denn einige Große wissen noch mehr als wir und verkaufen
sehr stark, selbst auf diesem niedrigen Stand.
Warum wohl??
Marco

[extrader78]

@marco111
super aussage. Wo bitte ist caly bei hohen umsätzen 8% ins minus gerutscht...???? WOOOOOOOOOO das waren sehr sehr wenig umsätze....Da weis keiner mehr...halt dich hier bitte mit deinen aussagen zurück die du nicht belegen kannst!!!kurs 0,215 bei bid 0,22 und ask bei 0,23$$ du versucht hier nur eins ....den kurs mit haltlosen aussagen zu drücken um selber günstig einzusteigen oder nachzulegen!!!lies doch mal deine anderen beiträge durch!!!
Caly ist auf dem besten weg gross rauszukommen und da änderst du mit deinen aussagen schon gar nix dran.

[rjenzi]

@biologist

Danke fuer Deine Antwort. Sehe das Ganze aber in einem andern Licht. Die von Dir erwaehnte Kosten werden (bitte korrigiert mich, wenn ich Stunk erzaehle)unter dem folgenden Punkt verbucht: "Selling, general and administrative costs". Unter "Cost of Product Sales" sollten eigentlich nur Kosten, die direkt mit der Herstellung des Produkts zusammenhaengen, verbucht werden...

Und wenn ich so die Vergangenheit bei CALY anschaue, dann waren die direkten Kosten immer mind. so hoch wie der Umsatz der damit generiert wurde. Dieser Umstand finde ich doch recht bedenklich...

[biologist]

@rjenzi

Ups, Du hast recht. Da könnte ich doch tatsächlich falsch liegen. Nur wenn`s die Produktionskosten sind, werden die bei hohen Stückzahlen sinken. Warten wir mal ab, was sich tut und ich forsche noch mal nach....

Stay tuned

biologist

[rjenzi]

@biologist

Ich wuerd auf jeden Fall vorsichtig sein mit diesem Wert. Die Story toent zwar interessant... Aber die Kostenseite muss dringend verbessert werden. Dies habe ich noch gefunden, was die These von hohen Fixkosten stuetzen wurde:

"I asked about capacity `cause I wanted to know how much of it they were going to be using when they hit profitability. If I heard correctly, the 14 to 16 million in 2002 would be at about 20%. And that`s with one shift. So to hit profits at that low of a % of full capacity, is incredible. "

Allerdings weiss ich nicht, was der Schreiber mit 14 - 16 Mill. meint... Ich glaube, das Beste ist, wenn man zuerst abwartet (bzw. nur minimal investiert ist) und sieht, ob die Firma es schafft positive Bruttorenditen zu erwirtschaften.

Unschoen ist auch, dass Ende September ein institutioneller Anleger (H&Q HEALTHCARE INVESTORS)ausgestiegen ist (Verkauf von 1 Mill. Aktien).

[www.hagelshop.1a.gs]

Abwarten und Tee trinken dann auf caly ist verlass!!!!!
Das ist meiner meinung nach die ruhe vor dem Sturm!!!!!
jahres schlusskurs wird so bei 0,52 liegen!!!!!
abwarten und viel viel tee reinpressen!!!

MFG:



www.hagels-shop.1a.gs

[idtde]

Interessanter Weise in Frankfurt heute 0.29, wer kauft denn so teuer ?? Wenn man Nasdaq OTC nimmt, wäre 0.25/0.26 realistisch, oder gibt es was, was wir nicht wissen???

[Dr.Schmutz]

Hallo zusammen,

heute passiert drüben in den Staaten für diese Uhrzeit ja
richtig was. Ist es wirklich das Licht am Ende des Tunnels
oder steht da einer mit dem Flammenwerfer ?

9:37:00 AM Trade (at Ask) 0.235 10000 OTC BB
9:36:18 AM Trade (at Bid) 0.23 5000 OTC BB
9:36:18 AM Trade (at Ask) 0.235 5000 OTC BB
9:35:43 AM Trade (at Ask) 0.235 5000 OTC BB
9:35:37 AM Bid 0.23 5000 OTC BB
9:35:15 AM Trade (at Bid) 0.225 100 OTC BB
9:33:35 AM Ask 0.235 5000 OTC BB
9:33:35 AM Bid 0.225 5000 OTC BB
9:33:35 AM Ask 0.235 5000 OTC BB
9:33:35 AM Bid 0.225 5000 OTC BB
9:33:10 AM Trade 0.23 20000 OTC BB
9:33:05 AM Trade (at Ask) 0.235 10000 OTC BB
9:33:02 AM Ask 0.235 5000 OTC BB
9:31:29 AM Trade (at Ask) 0.23 10000 OTC BB
9:31:21 AM Trade (at Ask) 0.23 1500 OTC BB
9:30:37 AM Trade (at Ask) 0.23 5000 OTC BB
9:30:06 AM Trade (at Ask) 0.23 5000 OTC BB
9:30:05 AM Trade (at Ask) 0.23 100 OTC BB
9:29:42 AM Bid 0.225 5000 OTC BB

Bis denne,
Schmutz

[tst89]

NEWS:

Calypte Secures Additional Equity Financing; Investors Include Members of Calypte Board And Management

November 28, 2001 18:02:00 (ET)

ALAMEDA, Calif., Nov 28, 2001 (BW HealthWire) -- Calypte Biomedical Corporation (CALY, Trade) announced today that it has completed a Regulation D private placement of approximately 1.6 million shares of its common stock at a price of approximately $0.19 per share. Calypte will receive approximately $295,000 in net proceeds from the private placement. The shares will be restricted securities under federal securities rules and the investors will be required to hold the shares for at least one year before they can sell the securities pursuant to an exemption from registration unless Calypte chooses to register the shares for resale. Calypte currently has no plans to register the securities. In return for accepting these restrictions, the shares were sold to investors at a discount of $0.037 per share from the market price.

Nancy Katz, Calypte`s President and CEO, stated that the funds raised in this private placement will be used in Calypte`s ongoing operations. The monies will serve as a bridge in the overall financing strategy.

Over half of the proceeds of the financing include investments from members of the Board of Directors and top management of the company, including Ms. Katz.

[Gobshite]

Another Press Release

Business Editors & Health/Medical Writers

ALAMEDA, Calif.--(BW HealthWire)--Nov. 28, 2001--Calypte Biomedical Corp. (OTCBB:CALY) announced today it intends to offer up to $10 million of shares of its common stock to international investors pursuant to Regulation S of the Securities Act of 1933. The shares of common stock will be priced at a discount to the current market price with final pricing and terms to be determined in the course of the offering.
The offering of the stock is currently anticipated to close during the first quarter of 2002, subject to market conditions. The offering will be conducted exclusively outside of the U.S. and will be open only to non-U.S. persons under Regulation S. The offering has not been, and will not be, registered under the Securities Act and the equity included in the offering may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The Company plans to use the proceeds from the offering to fund its continuing operations.

[biologist]

@all

Also, die neuen News bedeuten nichts Schlimmes. Zusätzliche Ausgabe von 1.6 Mio. neuen Anteilen zu $0.19 sieht erst einmal schlimm für den Kurs aus. ABER: Die Anteile werden von privater Hand gehalten, gelangen also nicht in den offiziellen Handel, UND müssen für mindestens ein Jahr gehalten werden! Und in dieser Zeitspanne kann sich VIEL tun.
Glücklich kann sich also der schätzen, der hier zu diesen Konditionen eingestiegen ist!

biologist

[tst89]

HIV testing low among those most at ris

11/29/2001



Study: HIV testing low among those most at risk

ATLANTA (AP) — Only about half the people at highest risk for HIV have been tested, suggesting U.S.
infection rates could be higher than health experts thought, government researchers said Thursday.

Just 54% of people who reported being at high or medium risk said they had been tested for the virus that
causes AIDS, the Centers for Disease Control and Prevention said.

An even smaller proportion of the risk group — less than 25% — said they had been tested in the previous
year. The study was released in advance of World AIDS Day, which is Saturday.

The results underscore a problem that has concerned health officials for years: A substantial segment of
people with HIV don`t even realize they have it and are probably spreading the infection.

The study cited lack of access to testing centers and a perceived lack of confidentiality as reasons some
people don`t get tested.

The risk factors for HIV included injection drug users, people who trade sex for money or drugs, men who
have sex with other men and people with blood-clotting problems. Anyone who had sex with someone in
the risk categories was also considered at risk.

The CDC study, conducted in 1999, asked more than 30,000 people whether they fit into any of the
categories. Those who did were deemed at risk for HIV and asked to rate their risk.

In encouraging news, about 30% of people in the study said they had been tested for HIV, up from 26% in
1995 and just 5% in 1987, when AIDS was perceived to be mostly isolated among homosexual men.

Still, only 10% of those in the overall study said they had been tested in the previous year.

HIV testing rates appear to be higher for blacks than for whites. More than 70% of blacks at highest risk
for HIV in the study said they had been tested, compared with 63% for Hispanics and just 50% for whites.

The study also found that blacks were most likely to seek an HIV test because they just wanted to know
their HIV status, while whites were most likely to test because it was required for a job, surgery, insurance
or military service.

Hispanics were roughly split among those two reasons and testing because it was recommended by a
doctor or a sexual partner.

Blacks and Hispanics have accounted for more than half of the 775,000 AIDS cases reported in the United
States since the epidemic began 20 years ago.

[Marco111]

Jungs das ist doch genau warum Caly nicht steigen wird
im den nächsten 12 Monaten.
Es werden viele Milionen neue Aktien herausgegeben.
dann auch noch zu 0,19 $.
Das wäre ja sich unbedenklich aber das KGV der Firma wird
genauso explodieren, wie die deutlich schlechter ansteigenden Gewinne.
Caly hat viel zu hohe Produktionskosten, wirft also auch später nur sehr wenig Gewinn ab, im Verhältnis zum Umsatz.
Doch schlimm ist wirklich, dass bis zu 200.000.000 Mio neue
Akien herausgebracht werden, da sind dann selbst 0,19 noch
zu teuer.
Marco

[tst89]

AIDS continues `devastating` sweep

December 1, 2001 Posted: 12:42 PM EST (1742 GMT)

------------------------------------------------------------------------



------------------------------------------------------------------------

LONDON, England (CNN) -- The virus that causes AIDS is continuing to spread worldwide at a dramatic pace, with eastern Europe particularly hard hit, the United Nations has warned.

The U.N. report, released to coincide with World AIDS Day on Saturday that aims to raise global awareness of the disease, revealed that 75,000 new infections of the virus that causes acquired immune deficiency syndrome had been reported in Russia by early November, a 15-fold increase in just three years.

The U.N. also warned that AIDS was continuing to spread worldwide at a dramatic pace, with 40 million children and adults infected by HIV, an increase of four million from last year.

Dr Peter Piot, executive director of the U.N. programme on HIV/AIDS, UNAIDS, warned: "HIV is spreading rapidly throughout the entire Eastern European region.

MORE STORIES
Mandela in AIDS drugs appeal 
China protesters greet AIDS Day 
 

EXTRA INFORMATION
• AIDS: 20 years of an epidemic 
• Timeline 
• Flash: How HIV infects cells 
 
 QUICKVOTE
Will World AIDS Day do any good?
Yes
No
View Resultsvote 

"It is unequivocally the most devastating disease we have ever faced and it will get worse before it gets better."

In an interview published in a Russian newspaper on Saturday, Piot said millions in Russia could die from AIDS over the next decade if the government does not take fundamental steps to fight the spread of the disease.

"All will depend on which position the leadership of the country takes," Piot told the newspaper Vremya.

European Union trade chief Pascal Lamy said the EU was determined to do all in its power to make sure that safe, affordable drugs were available to all who need them in the struggle to combat HIV-AIDS and other killer diseases.

Ukraine`s Health Minister, Vitaliy Moskalenko, said that three government anti-AIDS programmes between 1992 and 2000 slowed the epidemic, while the current 2001-2003 program may even stop it, according to the Interfax news agency.

The current programme in Ukraine has focused on AIDS prevention measures among youth and removing the stigma associated with the disease.

Piot praised Ukraine`s achievements but warned that the situation may worsen among the youth, Interfax reported.

The United Nations estimates that the number of victims in Ukraine has risen from 110,000 in 1997 to as many as 240,000 in 1999.

The Christian agency World Vision called on Saturday for the church to take a more realistic attitude to the use of condoms in an attempt to slow the global spread of the disease.

And in Kenya, doctors are trying to convince men to tell their wives if they are HIV-positive in an effort to reduce the spread of the disease, Dr. James Nyikal, chairman of the Kenya Medical Association, said.

There are more than two million HIV-positive people in Kenya`s population of 30 million. Many married Kenyan men have more than one wife or have multiple sexual partners.

Across Africa there were 3.4 million new infections with more than 30% of pregnant women in some areas HIV positive.

Unknowing infection

In Trinidad, Dr. Ruben Del Prado, regional programme adviser for UNAIDS, said Caribbean governments must relax laws criminalising homosexuality and prostitution if they hope to combat AIDS.

Gays and prostitutes "will not come forward to be tested, educated and to be treated, because there are laws against them," Del Prado told The Associated Press.

The Caribbean, excluding Cuba, has an HIV infection rate of nearly 2 percent -- the second-highest regional rate after sub-Saharan Africa. About 500,000 people in the Caribbean live with the disease; by contrast, aggressive campaigns in Cuba have kept infection rates there low.

In the United States, the federal Centers for Disease Control and Prevention reported on Thursday that nearly 30 percent of people deemed at risk for HIV have never been tested and could be unknowingly spreading the virus that causes AIDS.

The study involved more than 30,000 people in the United States. Some 73 percent of those considered at risk for HIV said they had been tested, but only 30 percent said they had been tested in the previous year.

In Thailand, the government bowed to AIDS patients` demands on Friday and agreed to provide AIDS treatment under a government programme that offers medical care for 30 baht (70 U.S. cents) per hospital visit.

Thailand is credited with bringing down its rate of HIV/AIDS infection by 80 percent after a massive awareness and condom distribution campaign in the early 1990s.

Heterosexual spread

Meanwhile in Britain, research from Taylor Nelson Sofres Healthcare (TNSH) showed that 54% of all new HIV infections were from heterosexual sex. Previously most infection had been caused by intravenous drug use or homosexual sex.

The HIVDynamics Monitor study detailing more than 2,000 HIV patients in France, Germany, Italy, Spain and the UK, shows infection through heterosexual contact has also increased in Italy rising from 28% last year to 47% this year.

In Spain and Italy over half (52%) of all HIV infections are due to drug abuse compared with just 7% in the UK.

Spain and Italy also report much lower transmission rates through homosexual contact than the rest of Europe (18% compared with 50% in Germany and 40% in the UK).

UK government data shows that more than 33,000 Britons aged 15 to 59 have HIV -- 10% above the estimate for the end of 1998. This is believed to be the most since records began in 1982.

[tst89]

China Ends AIDS Silence, Mandela Calls for Drugs
December 01, 2001 03:16 PM ET

LONDON (Reuters) - A veil of secrecy still shrouds AIDS in some countries 20 years after it first reared its head but on Saturday China, the latest convert to openness, marked World AIDS Day by airing a shocking TV drama on the disease.

In South Africa, where more people live with HIV/AIDS than in any other country and the government is widely criticized for its ambiguous stance, former president Nelson Mandela called for victims to be given access to drugs that fight the disease.

"Nothing threatens us more today than HIV/AIDS...AIDS is a scourge threatening to undo all the gains we made in our generations of struggle," said Mandela, who headed the country`s first post-apartheid government.

Close to five million people, or one in nine of the population, are affected in South Africa by the human immunodeficiency virus, HIV, or the Acquired Immune Deficiency Syndrome that it invariably leads to.

World AIDS Day was marked by pressure groups and governments alike, and included calls by a group of Indian prostitutes for their profession to be legalized. In the Seychelles, the government announced it would offer free antiretroviral drugs.

In 16 countries, more than one 10th of people aged 15-49 are infected with HIV. Worldwide, more than 40 million people live with HIV or AIDS, including 4.5 million children.

Twenty years after scientists in the United States reported first clinical evidence of the disease, there is no still cure.

ABOUT-TURN IN CHINA

While the Chinese infection rates do not compare with the devastating statistics from Africa, Beijing has made a dramatic about-turn in recent months.

The world`s most populous country was jolted into action after HIV infections surged 67.4 percent to 3,541 in the first half of 2001.

"This year the government has really stepped up its fight against AIDS because of the global situation," said AIDS expert Zhang Konglai, a professor at the Peking Union Medical College.

China`s first television drama on AIDS, which had a potential audience of 92 percent of China`s population of 1.3 billion through state-owned China Central Television, was partly a scare tactic.

But it also contained more subtle messages about a disease which threatens to escalate into a major epidemic in a country where there is still widespread ignorance about it.

The United Nations says China could have 10 million HIV/AIDS sufferers by 2010 unless it acts decisively.

Mandela, 83, cuddled infected and dying children at a shanty home and answered questions from black and white children.

Africa`s most respected statesman insisted repeatedly in his answers to their questions that the government should provide drugs to prolong the lives of people already infected with HIV.

His forthright comments contrasted sharply with current president Thabo Mbeki`s ambiguous stance on the issue.

"For those who are HIV-positive, we must ensure that they get the proper treatment and drugs which are going to help them resist the pandemic," Mandela said.

The country`s foremost AIDS lobby group, the Treatment Action Campaign (TAC), welcomed Mandela`s comments as "a subtle message to Mbeki."

"This comment would not have been made without realizing it is in contrast with what Mr. Mbeki has been saying," said TAC national secretary Mark Heywood. Mbeki has repeatedly voiced the view that anti-AIDS drugs are expensive, dangerous and unproven.

DRUGS FOR AFRICA

U.S. drug giant Pfizer Inc said it would sign agreements with six African countries in the next three months to provide its antifungal drug Diflucan free to AIDS sufferers.

The program will be extended beyond South Africa to Botswana, Lesotho, Malawi, Uganda, Namibia and Swaziland.

Pope John Paul, leader of the world`s Roman Catholics, said people with AIDS should not feel alone in their suffering and called for greater awareness of the causes and consequences.

Under John Paul, the Vatican has been unbending in its opposition to all forms of artificial contraception, including condoms which are seen by many health experts as a key tool in the battle against AIDS.

The church has always preached abstinence from extra-marital sex as the best way to prevent transmission of the virus.

But in devoutly Catholic Portugal, which has the highest infection rate in the European Union, the church put AIDS prevention before moral stricture, urging couples to have blood tests before beginning a stable relationship, "in marriage or otherwise."

Meanwhile, a group of prostitutes in Calcutta urged authorities to legalize their profession, saying it would improve access to medical facilities and reduce the incidence of AIDS. A recent U.N.-funded report said an "explosive" AIDS epidemic had hit Asian sex workers.

[Triceratops]

Calypte hat einen Vorteil gegenüber anderen Aktien. Bei einen Totalverlust kann ich mir ja einreden, daß es für eine gute Sache war.

[sunny66]

Servus zusammen!
Kann mir vielleicht jemand sagen, wann die Q.4-Zahlen rauskommen??? Würde natürlich gerne noch etwas in Caly investieren - bin auch sehr von Caly`s Geschäft überzeugt.
Ist doch bestimmt eine gute Mittel- bis Langfristanlage.
Wenn das Produkt von Caly erst so richtig populär wird und weitere Märkte erschlossen werden, dann werden sich die Leute verdammt ärgern, die nicht zeitig eingestiegen sind. Allen Calys das Beste!!!
Su.

[Marco111]

Und wieder steigt leider der Umsatz und die Kurse fallen.
Habe heute mit Laborleiter über den "so tollen" Urintest
gesprochen.
leider ist eine Trefferquote von 97,3 % bei dem Test sehr schlecht da viel zu ungenau.

Stell Dir vor Du gehst zum Arzt und er sagt Dir nach dem Test alles ok kein HIV und nach 4 jahren stellt sich leider raus, Du bist es doch und hast dann aber etwa 25 Frauen angesteckt und die wieder je 4 weitere Männer im Durchschnitt.
also über 100 Menschen wieder angesteckt, weil DU einen Test hast machen lassen, der nur 97 % sicher ist.

Wer heute eine Diagnose ob er HIV hat oder nicht braucht,
der muss sich zu 130 % auf die Aussage verlassen können.
Keine Lebensversicherung wird nur um 5 Euro zu sparen sich auf 97 % verlassen, wenn sie durch Bluttest nach 2 Tagen 100 % erreicht.
Ich habe darüber nachgedacht und denke wenn Caly keinen 100%
Test hat wird die Firma leider sich nur sehr schwer tun von den Labors akzeptiert zu werden.
Ich denke das noch so viele Aktien bis zu 200.000.000 Mio
Stück rauskommen ist ein 2 schlechtes Zeichen.
KGV leider dann viel zu hoch
Überzeugt mich eines besseren!
Marco

[Tandil]

Ich denke, 97% für eine Versicherung sind ausreichend. Rest ist "Restrisiko" zu Lasten der Versicherung. Natürlich nicht akzeptabel für eine Arztpraxis. Da muß es schon 100% sein. Aber in diese Schiene wollte CALY ja nie rein. Der Schnelltest sollte nie den normalen Bluttest ersetzen. Die Stärke liegt woanders. Das schnelle Durchscannen von Bevölkerungsgruppen um einen Überblick über die Verbreitung von Aids zu bekommen. Das ist die Stärke von CALY. Das kann man nicht mit einem Bluttest machen, da die Kosten viel zu hoch wären.

mfg

[Tandil]

Ein Beispiel:

Die chinesische Regierung will wissen, wie hoch der Aidsbestand in ihrer 5 Mio Mann starken Armee ist. Das kann mit nicht mit einem Bluttest machen. Mit dem Urin-Test haben die das Ergebnis in 5 Tagen. Dazu reicht die 97% Sicherheit aus. Der Rest wird hochgerechnet.

Was ich sagen will.
- Schnelltest zum Durchscannen;
- Bluttest zum verifizieren und behandeln

mfg

[Tandil]

Noch ein Beispiel:

Die WHO will in Zusammenarbeit mit der indischen Regierung wissen ob die Ausbreitungsgeschwindigkeit von AIDS in Kalkutta ab.- oder sogar zunimmt. Dazu wird, alle 2 Jahre an 10.000 statistisch herausgesuchten Bewohnern, ein Urin-Test durchgeführt. Über das Ergebnis kann man auf ganz Kalkutta schließen und die entsprechenden Maßnahmen einleiten.

mfg

[tst89]

Lauter gute News und der Kurs sinkt und sinkt....

die Verwässerung des Kurses durch die neuen Aktien verunsichert wohl immer mehr Leute.....mich auch........

Entweder Calypte fängt sich langsam und steigt ordentlich oder ich sehe da zukünftig ein ewiges hin und her zwischen 0,19 - 0,22$.

Gruß
tst

[thorulte]

Hi Leute,

etwas verunsichert hat mich die Meldung, dass Calypte das Haltbarkeitsdatum des Urin-Tests um 3 Monate verlängert haben will.
Man könnte das eventuell auch als einen Hinweis darauf sehen, dass die ihr Zeug einfach nicht los werden - sprich: Ladenhüter!!

Oh je, und dann noch die Ankündigung, Aktien für 0,19$ rauszugeben. Sieht nach einem Ausverkauf aus.
Nach dem Motto: Mal sehen, wem wir unseren Schrott noch andrehen können.

Es fällt mir schwer, bei solchen Meldunge noch optimistisch zu bleiben.
Nix für ungut, ich hoffe von ganzem Herzen, dass ich mich irre.

So long,
thorulte

[Boersenkraehe]

@Thorhulte

Was erzählst du eigentlich für ein Quatsch? Die Aktien sind bereits auf dem Markt! Weniger als erwartet! Haltefrist 1 Jahr! Dafür gab es einen Abschlag! Deshalb 0,19 !!!! Die Furzanteile die momentan gehandelt werden, kommen von solchen Insidern wie du es bist. Das ask 0,22in usa ist nicht Aussagefähig! Der fette Brocken hält weiterhin bei 0,25 $! Informiere Dich im Thread, bevor Du solchen Senf von Dir gibts.

Caly is future

Nix Gruß

[david1]

@ Boersekraehe

mittlerweile beachte ich die dummen Aussagen gar nicht mehr.
Der absolute Gipfel ist der User Marco111.
Da erlaube ich mir sogar die Aussage, dass er entweder nicht richtig lesen kann, oder er hat immer noch nicht
begriffen, um was es hier bei Caly überhaupt geht.

Reg Dich nicht nicht auf, denke immer:
Der lieber Gott hat den Menschen geschaffen,
hat sich aber dies nicht patentieren lassen.
Jetzt kann das jeder nachmachen und so was kommt dann raus.

Gruss David

[Marco111]

Leider reichen auch zu Massentest die 97 % Sicherheit nicht aus. Jeder der dann getestet wird, hat ein Recht auf ein sicheres Ergebnis und da muss man nun mal auf 100% bestehen.

Caly wird von den Labors nicht akzeptiert und auch von den Lebensversicheren nicht.
Die werden sicher lieber 5$ mehr ausgeben, wenn sie nach 2 Tagen aber 100% Sicherheit haben,, als eine Milionenklage auf den Tisch.
Das Caly nun das MHD verlängern will spricht leider für volle Lagerbestände, was sich auch im Kursverlauf der letzten 3 Monate wiederspiegelt.
Die Produktionskosten sind höher als der viel zu schwache
Umsatz. Wenn nun noch 200.000.000 MIO Aktien ausgegeben werden, ist das mehr als schlimm da das KGV abnormal steigt.

der Test ist schon seit 3 jahren auf dem Markt doch leider ist die Akzeptanz gleich null.
Außer einige 3 -Länder kaum Umsatz und sich als Privatmensch auf 97 % zu verlassen, ist mehr als gefährlich.
Wenn dann der Test negativ ist, wäre es sehr gefährlich doch zu den 3 % zu gehören.
Wenn keine 100% schnell erreicht wird, ist Caly bald am Ende.
Doch es wissen viele in den USA mehr und einige große gehen raus.
Caly hat auch den versprochenen Großinvestor nicht gefunden weil dieses Produkt kaum keiner will.
HIV muss man zu 100% testen, sonst ist alles nur fahrlässig und kann nicht länger geduldet werden und darf auch nicht als Massenartikel auf den Markt.
Denn die 3 % spielen fahrlässig mit dem Leben anderer.
Aus diesem Grund wird es auch keine Zulassung in Europa geben können.
Späte Einsicht ist besser als keine !
aber ich bin auf gegenteilige Meinungen immer gespannt David
Gruß
Marco

[david1]

@ Marco111
Lieber Gott, verzeih Ihm, da er nicht weiß, was er redet.

Oh ja ! Das Produkt ist seit 3 Jahren auf dem Markt?
Und die FDA Zulassung hat es seit Christi Geburt !!!
Lesen kannst Du nicht und denken schon gar nicht, was hast Du für eine Schulbildung?

Und noch was, hast Du schon irgendein Test gesehen
das 100% ist? Menschen mit normalem IQ (es reicht schon um die 70) wissen, dass jeder Test, egal ob HIV, Hepatitis,
ob Bluttest oder Urintest nur 98%-tig ist, da die 0,02% als Restrisiko darstellt, und dient zu Absicherung.
Ja, aber Menschen wie Du lesen nicht, die labern immer wieder die gleiche Scheiße, ohne nachzudenken.

Ich möchte Dich nur drauf aufmerksamm machen, dass
das Verbreiten von Falschmeldungen etc. ist auch im
Internet strafbar und wird ggf. entsprechend geahndet.
Also!
Immer schön Vorsichtig, das kann für Dich sehr teuer sein.

[zerro]

hallo zusammen,
sind es nicht 99,7% sicherheit???

gruss zerro

[zerro]

Calypte Biomedical Corporation is engaged in the development of a urine-based screening test for the detection of antibodies to the Human Immunodeficiency Virus, Type-1 (HIV-1), the putative cause of Acquired Immunodeficiency Syndrome (AIDS). The Company has integrated several proprietary technologies to develop a test that, in clinical trials, detected the presence of HIV antibodies in urine with 99.7% sensitivity in subjects known to be HIV-1 infected, as identified through blood-based (serum/plasma) screening tests. The Company estimates that the cost of collecting, handling, testing and disposing of urine specimens will be significantly less than that of blood specimens.

http://biz.yahoo.com/p/c/caly.ob.html

gruss zerro

[david1]

@ zerro
Es ist egal, wie viel Prozent das Restrisiko darstellt.
Bei eine Impfung,haben wir auch keinen 100%-gen Schutz.
Bei eine Verhütung sagt man zwar auch 100% sicher,
aber Restrisiko ist immer vorhanden.

David

[david1]

AN ALLE CALY USER

Der User Marko111 verbreitet hier im Caly Board Unwahrheiten und Falschmeldungen.

Calypte ist nicht mit dem HIV Urintest seit 3 Jahren
auf dem Markt, sondern erst seit der FDA Zulassung
27.06.2001.
------------------------------------------------------------
28.06.2001
Calypte Biomedical, WKN 909402, NASDAQ: CALY, hat gestern unerwartet die FDA Zulassung für einen Urintest zur Detektion von HIV-1-Antikörpern entwickelt, der eine Zuverlässigkeit von 99,7 % besitzt, bekommen.
Es ist davon auszugehen, daß die HIV-1-Analyse mit einem Urintest sehr viel schneller, billiger und zuverlässiger erfolgen kann, als mit einer entsprechenden Blutuntersuchung. Aufgrund der weltweiten HIV-Problematik dürften die Absatzmärkte für ein solches Produkt enormen Potential haben.

Gruss David

[zerro]

hallo zusammen,
richtige chancen sehe ich bei caly erst, wenn die vermarktung dieser produkte
auf die richtige schiene kommt.
es gibt sehr viele leute, die einen seitensprung haben oder hatten.
wenn es für diese leute eine möglichkeit gäbe, dieses produkt ( aids-test )
ANONYM zu beziehen (z.b. wie bei den kondom-automaten oder über einen versandhandel),
würde ich für caly eine sehr große zukunft sehen.

betr. 99,7% test-sicherheit:
falls ein proband , positiv getestet sein sollte.
wird er auch bei einer 100% test-sicherheit, andere test-systeme verwenden.
( weil er es nicht wahr haben möchte. )

gruss zerro

[extrader78]

in berlin seit donnerstag bid 0,22€ and Ask 0,28€
langsam wirds mehr als nur langweilig hier!!! @david weist du wann genau die 01 zahlen kommen.so weit wie ich mich informieren konnte kamen die für 00 erst heuer im märz.

[extrader78]

was soll den die sch... jetzt minus 20% !!! wer verkauft da für 0,20€ ???? und warum??jetzt reichts langsam

[Boersenkraehe]

Jetzt wirds wieder interessant!!

Mal schauen ob es noch weiter geht?

Z.Z. 0,23 $

Gruß Börsenkraehe

[Palerm]

Hallo Calypter,
bis jetzt fast 200.000 Stück gehandelt. Ist ja immerhin ein Fortschtritt im Gegensatz zu der letzten Börsenwoche.
Es muß sich doch irgendwann mal in Richtung Norden etwas bewegen.
Palerm, der mit dieser Aktie noch wahnsinnig wird.

[extrader78]

hahahaha @palerm........ich auch bald oder ich bins schon...!!den heutigen tag könnte man echt im calykalender ankreuzen

[NM-Expertentip]

Jetzt ist es Zeit zum einsteigen.
Sieht ja ganz gut aus heute !!!

[tst89]

Ohne News fast +15%.........

Was jemand was????

[chartwaechter]

Hallo Calyptefreunde,
schon die News gelesen?
http://finance.yahoo.com/q?s=CALY.OB&d=t
MfG

[Palerm]

Kann einer was damit anfangen? Mein Englisch ist nicht so, dass ich das verstehe. Ich nehme an es sagt etwas über den Umsatz und der Liquität von Caly aus, oder?
Palerm, der sich nur noch wundert.

[jojobada]

Hallo palerm
kannst Du den Artikel über Caly bitte hier hinein stellen ich schau ihn mir mal an.
Danke im voraus

leise ist es hier im Board keiner sagt auch nur ein Wort
willst Du caly steigen sehen mußt Du nur in diesen Board rein gehn

zur Zeit ist nirgendwo was los alle sind in Enron rein schau doch mal vorbei
851914 wkn
ich bleib aber bei caly drin auch wenn es noch ein jahr dauert werde bald nachkaufen!!!

mfg jojo

[Palerm]

@jojobada,
ich denke das gestaltet sich äußerst schwierig, da es sich um Tabellen handelt. Kopier den Link von Chartwaechter einfach rein; Dann wird die Seite aufgerufen. Oder besser:

http://biz.yahoo.com/fin/l/c/caly.ob.html

Mit der Ruhe hast du recht, aber ich hoffe das legt sich. Bis jezt knapp über 140.000 Stück in USA gehandelt. Also ein Tag fast wie immer.
Ciao
Palerm

[extrader78]

10:10:38 AM Trade (at Ask) 0.23 20000 OTC BB
10:10:28 AM Trade 0.22 30000 OTC BB
Das nenne ich mal richtige trades,weiter so

[extrader78]

10:10:38 AM Trade (at Ask) 0.23 20000 OTC BB
10:10:28 AM Trade 0.22 30000 OTC BB
Das nenne ich mal richtige trades,weiter so

[Palerm]

@extrader78,
kannst du mir bitte schreiben wie du diese Daten herbekommst. Ich habe schon öfters gelesen, das dies an der OTC möglich ist allerdings konnte ich nie so richtig erfahren wo. Danke im Voraus.
Palerm, der gerne wüßte wie man noch näher an der OTC ist.

[extrader78]

@Palerm
http://quotes.freerealtime.com/rt/frt/M?SA=quotes|Time%26Sal…

Diesem Link folgen...www.freerealtime.com.....da musst du dich kurz anmelden und unter caly... rechts --->times and sales wählen....

[extrader78]

@palerm
sorry ich meinte natürlich dann links times and sales auswählen,nicht rechts

[chartwaechter]

Calypte = Langeweile ohne Ende?

Es ist gar grausig den Chart anzusehen,
denn Caly will sich nicht vom Fleck begehen,
immer nur derselbe Chart,
die Zahlen haben einen ganz langen Bart.

Mir fällt weiter dazu nichts mehr ein.
Chartwaechter

[tst89]

Tja sollte dass lange warten endlich ein Ende haben??

+35,2% an der OTC nach der News von gestern und die VOR Bekanntgabe der Zahlen.....

Gibt ja mal wieder Hoffnung

Gruß
tst

[tst89]

Heute bin ich mal gespannt wie Calypte nach den Gewinnmitnahmen von letztem Freitag in diese
Woche starten wird. Wir befinden uns ja leider nach diesen Gewinnmitnahmen UNTER der
100-Tages-Linie, aber immer noch deutlich über der 38-Tages-Linie